Add to ORKGA Discussion of Unigene Laboratories, Inc. v. Apotex, Inc.: The Standard for Prima Facie Obviousness of Pharmaceutical Formulation Claims in a Post-KSR Worl
One of the most important and delicate judicial tasks in patent law is to keep the obviousness doctr...
The Supreme Court of Canada recently revised the doctrine of non-obviousness in a pharmaceutical se...
[Excerpt] “The question of whether an invention is an obvious variation of existing technology is on...
A Discussion of Unigene Laboratories, Inc. v. Apotex, Inc.: The Standard for Prima Facie Obviousness...
This Article considers the effect of the recent decision of the U.S. Supreme Court in KSR Internatio...
Pharmaceutical companies depend on patent protection to recuperate the high costs of research and de...
One of the most important and delicate judicial tasks in patent law is to keep the obviousness doctr...
In KSR International Co. v. Teleflex, Inc., the Supreme Court rejected the Federal Circuit\u27s rigi...
This Comment proposes the use of a specifically tailored obviousness standard as a new solution to t...
Pharmaceutical research often entails making small modifications to candidate drug molecules--modifi...
In KSR International Co. v. Teleflex Inc., the Supreme Court adhered to its prior views that a const...
In Apotex Inc v Sanofi-Synthelabo Canada Inc 2008 SCC 61, the Supreme Court held, affirming the lowe...
Most patents covering dermatologic products contain patent claims directed to the pharmaceutical for...
7-18‘Non-obviousness’ is a fundamental requirement of patentability under all patent jurisdictions a...
In SmithKline v. Apotex, the Court of Appeals for the Federal Circuit invalidated the main patent on...
One of the most important and delicate judicial tasks in patent law is to keep the obviousness doctr...
The Supreme Court of Canada recently revised the doctrine of non-obviousness in a pharmaceutical se...
[Excerpt] “The question of whether an invention is an obvious variation of existing technology is on...
A Discussion of Unigene Laboratories, Inc. v. Apotex, Inc.: The Standard for Prima Facie Obviousness...
This Article considers the effect of the recent decision of the U.S. Supreme Court in KSR Internatio...
Pharmaceutical companies depend on patent protection to recuperate the high costs of research and de...
One of the most important and delicate judicial tasks in patent law is to keep the obviousness doctr...
In KSR International Co. v. Teleflex, Inc., the Supreme Court rejected the Federal Circuit\u27s rigi...
This Comment proposes the use of a specifically tailored obviousness standard as a new solution to t...
Pharmaceutical research often entails making small modifications to candidate drug molecules--modifi...
In KSR International Co. v. Teleflex Inc., the Supreme Court adhered to its prior views that a const...
In Apotex Inc v Sanofi-Synthelabo Canada Inc 2008 SCC 61, the Supreme Court held, affirming the lowe...
Most patents covering dermatologic products contain patent claims directed to the pharmaceutical for...
7-18‘Non-obviousness’ is a fundamental requirement of patentability under all patent jurisdictions a...
In SmithKline v. Apotex, the Court of Appeals for the Federal Circuit invalidated the main patent on...
One of the most important and delicate judicial tasks in patent law is to keep the obviousness doctr...
The Supreme Court of Canada recently revised the doctrine of non-obviousness in a pharmaceutical se...
[Excerpt] “The question of whether an invention is an obvious variation of existing technology is on...